Evidence map›Paper›PMID 41731687›Full record

ArticleJournal of cellular and molecular medicine2026

The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti-HER2 Antibodies and Immunotherapy.

Panagiotis Sarantis, Aristofania Simatou, Ioanna A Anastasiou, Kostas Palamaris, Eleni-Myrto Trifylli, Evangelos Koustas, Christina Piperi, Michalis V Karamouzis, Athanasios G Papavassiliou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Panagiotis SarantisDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0001-5848-7905
Aristofania SimatouDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Ioanna A AnastasiouDepartment of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0002-7560-0575
Kostas PalamarisDepartment of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Eleni-Myrto TrifylliSecond Department of Internal Medicine-GI-Liver Unit, General Hospital 'Hippokratio', Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Evangelos KoustasOncology Department, General Hospital 'Evangelismos', Athens, Greece.
Christina PiperiDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Michalis V KaramouzisAcademic Department of Internal Medicine, General and Oncology Hospital 'Agioi Anargyroi', National and Kapoditrian University of Athens, Athens, Greece.
Athanasios G PapavassiliouDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in targeted therapies, resistance to anti-human epidermal growth factor receptor 2 (HER2) treatments remains a significant challenge in breast cancer (BC) management. This study aimed to evaluate the effectiveness of a triple-targeting regimen-Denosumab (D), Pertuzumab (P) and Trastuzumab (T)-for HER2-positive (HER2

Indexed as

Breast NeoplasmsDenosumabErb-b2 Receptor Tyrosine KinasesImmunotherapyReceptor Activator of Nuclear Factor-kappa BAnimalsAntibodies, Monoclonal, HumanizedCell Line, TumorFemaleHumansMiceTrastuzumabXenograft Model Antitumor AssaysAntibodies, Monoclonal, HumanizedDenosumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespertuzumabReceptor Activator of Nuclear Factor-kappa BTNFRSF11A protein, humanTrastuzumabbreast cancerDenosumabHER2immune checkpoint inhibitorsPertuzumabRANKRANKLTrastuzumab

Identifiers

PMID41731687
PMCPMC12929656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.